ArticleEJNMMI research2018
PET imaging of chemokine receptor CXCR4 in patients with primary and recurrent breast carcinoma.
Article in EJNMMI research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- Evaluating the diagnostic utility of [⁶⁸Ga]Ga-Pentixafor in solid tumors: a systematic review.Annals of nuclear medicine · 2025Pooled it
- Development of an Optimized CXCR4-Targeting Theranostic Pair.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- Radionuclide-based pharmaceuticals for breast cancer imaging: state of the art.EJNMMI radiopharmacy and chemistry · 2026Review
- Review
- ComparingCancers · 2025Article
- Radiotracer Innovations in Breast Cancer Imaging: A Review of Recent Progress.Diagnostics (Basel, Switzerland) · 2024Review
- Nanobiotechnology augmented cancer stem cell guided management of cancer: liquid-biopsy, imaging, and treatment.Journal of nanobiotechnology · 2024Review
- Advances in PET Imaging of the CXCR4 Receptor: [Seminars in nuclear medicine · 2024Review
- Research Progress of CXCR4-Targeting Radioligands for Oncologic Imaging.Korean journal of radiology · 2023Review
- Advances in PET/CT Imaging for Breast Cancer.Journal of clinical medicine · 2023Review
- The Role of PET/CT in Breast Cancer.Diagnostics (Basel, Switzerland) · 2023Review
- [Asia Oceania journal of nuclear medicine & biology · 2023Article
- [Cells · 2022Article
- Current Status ofDiagnostics (Basel, Switzerland) · 2022Review
- Review
- In Vivo Targeting of CXCR4-New Horizons.Cancers · 2021Review
- Potential for Increasing Uptake of RadiolabeledCancer biotherapy & radiopharmaceuticals · 2021Article
- Novel Agents and Future Perspectives on Theranostics.Seminars in radiation oncology · 2021Review
- Metastatic Heterogeneity of Breast Cancer: Companion and Theranostic Approach in Nuclear Medicine.Cancers · 2020Review
- A new class of PentixaFor- and PentixaTher-based theranostic agents with enhanced CXCR4-targeting efficiency.Theranostics · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundCXCR4 is a chemokine receptor frequently overexpressed in invasive breast cancer that has been shown to play a major role in signaling pathways involved in metastasis. The aim of this retrospective analysis was to assess the diagnostic performance of CXCR4-directed PET imaging in patients with breast cancer using the recently introduced CXCR4-targeted PET probe
resultsThirteen patients with first diagnosis of breast cancer, four patients with recurrent disease after primary breast cancer, and one patient with axillary lymph node metastasis of unknown primary underwent CXCR4-targeted PET imaging using
conclusionsCXCR4-directed PET imaging in patients with primary and recurrent breast cancer is feasible; however, tumor detectability is significantly lower compared to
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.